Psilocybin & Mental Health: Research, Evidence & Safety

A comprehensive, evidence-based guide to current research on psilocybin-assisted therapy for depression, anxiety, PTSD, addiction, OCD, eating disorders, and more — with critical contraindications and guidance on accessing clinical trials.

Condition-Specific Information

Explore research and considerations for specific mental health conditions. Always consult healthcare professionals before considering psychedelics, especially if you have an existing mental health condition.

Depression Anxiety PTSD Addiction OCD

Section 1: How Psilocybin May Affect Mental Health — An Overview

Mechanism of Action: 5-HT2A Agonism

Psilocybin is a prodrug that is rapidly converted in the body to psilocin, its active form. Psilocin acts primarily as a potent agonist at serotonin (5-HT2A) receptors, which are densely expressed in cortical regions of the brain, particularly the prefrontal cortex. This receptor activation is widely believed to underlie the perceptual, emotional, and cognitive changes associated with the psilocybin experience.

Unlike conventional antidepressants, which modulate serotonin availability over weeks, psilocybin causes a rapid, dramatic change in brain activity within 30–60 minutes of ingestion. This acute disruption of normal cortical signalling appears to reset certain entrenched patterns of neural activity — a hypothesis that has attracted considerable scientific attention as an explanation for the lasting therapeutic effects observed after even a single session.

Default Mode Network Suppression

One of the most consistently replicated findings in psilocybin neuroimaging research is a marked suppression of the default mode network (DMN) — a set of brain regions (including the medial prefrontal cortex, posterior cingulate cortex, and angular gyrus) that is associated with self-referential thinking, rumination, and the sense of a stable, bounded "self." In depression, OCD, addiction, and PTSD, the DMN is often characterised by excessive activity and rigid, repetitive patterns of thought — the endless loops of self-criticism, craving, or intrusive memory that define these conditions.

Psilocybin appears to temporarily disrupt these rigid patterns, increasing communication between brain networks that do not normally interact and allowing a period of heightened cognitive and emotional flexibility. Neuroimaging studies by Carhart-Harris and colleagues at Imperial College London demonstrated that subjective ego dissolution experiences correlate with the degree of DMN suppression, and that the magnitude of this disruption correlates with subsequent antidepressant response.

Psychological Flexibility and the ACT Model

The therapeutic benefits of psilocybin align closely with the concept of psychological flexibility from Acceptance and Commitment Therapy (ACT). ACT defines psychological health as the ability to contact the present moment fully, observe one's thoughts and feelings without excessive fusion with them, and act in accordance with one's values even in the presence of difficult internal experiences. Psychologically inflexible patterns — rigid self-narratives, avoidance of difficult emotions, experiential fusion with painful thoughts — are central to depression, anxiety, and addiction.

Psilocybin appears to temporarily loosen these rigid attachments, producing a period of openness during which patients may re-evaluate long-held beliefs about themselves and their lives. Many participants report that the experience provided a perspective-shift that allowed them to disengage from previously intractable self-critical narratives — an effect that, when supported by integration therapy, may persist for months.

Neuroplasticity: BDNF Upregulation and Dendritic Spine Growth

Beyond the acute period, psilocybin appears to trigger biological processes associated with neuroplasticity — the brain's ability to form new connections. Preclinical studies in rodents have demonstrated that psilocybin and other psychedelics increase expression of brain-derived neurotrophic factor (BDNF), a protein critical for neuronal growth, survival, and synaptic plasticity. Remarkably, a 2021 study by Ly et al. published in Cell Reports demonstrated that even low doses of psilocybin promoted significant dendritic spine growth in the prefrontal cortex of mice, with effects persisting for at least one month after a single administration.

If these neuroplasticity effects translate to humans — as early imaging data suggests they might — they could help explain how psilocybin produces lasting antidepressant and anxiolytic effects from just one or two sessions. This contrasts sharply with conventional antidepressants, which must be taken daily and typically take 2–6 weeks to achieve effect. However, it is important to note that direct evidence of dendritic spine growth in human brains following psilocybin remains limited, and much of the neuroplasticity hypothesis rests on preclinical data.

The Mystical Experience Component

A recurring finding across psilocybin studies is that participants who have a mystical or peak experience — characterised by feelings of unity, sacredness, noetic quality (a sense of having learned something profoundly true), deeply felt positive mood, and transcendence of time and space — show the largest and most durable therapeutic benefits. This has been assessed using validated instruments such as the Mystical Experience Questionnaire (MEQ-30).

This finding creates a philosophical and methodological challenge for the field: the most clinically effective doses tend to be those that produce the most intense experiences, which also carry the highest risk of challenging reactions. The relationship between mystical experience intensity and outcome is strong enough that researchers at Johns Hopkins have described a "complete mystical experience" as essentially predictive of positive outcomes in the addiction and depression literature.

Set, Setting, and Integration

Clinical psilocybin research does not simply administer a pill. Every major trial has incorporated a structured framework of:

  • Preparation: Multiple sessions with therapists before the psilocybin day, building trust, exploring intentions, and screening for contraindications.
  • Set: The participant's mindset, intentions, and psychological state on the day of the session.
  • Setting: A carefully designed therapeutic environment — typically a comfortable room with music, eye shades, and two trained therapists present throughout.
  • Integration: Multiple therapy sessions after the psilocybin experience to help the participant process and apply insights from the session.

This four-part structure is not window-dressing. Researchers consider it essential to both the safety and efficacy of psilocybin-assisted therapy. Outcomes reported in clinical trials almost certainly reflect the combined effect of psilocybin plus this therapeutic structure — not psilocybin alone. This is a critical caveat when interpreting the research literature.

Section 2: Psilocybin for Depression — The Research

Depression research represents the largest and most developed body of psilocybin evidence. Two broad populations have been studied: people with treatment-resistant depression (TRD) — defined as depression that has failed to respond to at least two adequate antidepressant trials — and people with major depressive disorder (MDD) who may not have exhausted conventional treatments.

Treatment-Resistant Depression: Carhart-Harris et al. 2016

The first modern open-label trial of psilocybin for TRD was published in The Lancet Psychiatry by Carhart-Harris and colleagues at Imperial College London in 2016. Twenty participants with long-standing, severe TRD (average duration over 17 years) received two doses of psilocybin (10mg and 25mg, one week apart) alongside psychological support. The primary outcome measure was the Quick Inventory of Depressive Symptomatology (QIDS-SR), a well-validated self-report scale where higher scores indicate more severe depression.

Results were striking: QIDS scores dropped from a mean of approximately 19 (severe depression) at baseline to approximately 7 (mild) at one week after the second session. At 3 months, 47% of participants met criteria for remission. Crucially, this was an open-label study with no control arm, meaning placebo effects and expectancy cannot be excluded. Nevertheless, the magnitude of response — in a population that had failed multiple prior treatments — attracted significant attention.

Psilocybin vs Escitalopram: Carhart-Harris et al. 2021 (NEJM)

A landmark randomised controlled trial published in the New England Journal of Medicine in 2021 directly compared psilocybin to escitalopram (a standard SSRI antidepressant) in 59 patients with moderate-to-severe MDD. Participants received either two psilocybin doses (25mg) plus daily placebo pills, or two very low (1mg) psilocybin doses (functioning as active placebo) plus daily escitalopram (10–20mg).

On the primary outcome (QIDS-SR at 6 weeks), the two groups did not differ significantly — both showed substantial improvement. However, psilocybin showed numerically larger improvements on all secondary outcomes (including response rate, remission rate, and wellbeing measures), and its effects appeared more rapidly. Critics noted the trial was not powered to detect differences between arms and may have been underpowered. Nonetheless, the finding that a two-session psilocybin protocol produced comparable antidepressant effects to six weeks of daily SSRI — while also being faster-acting — was considered clinically significant.

Major Depressive Disorder: Davis et al. 2020 (JAMA Psychiatry)

A Johns Hopkins team led by Alan Davis published a randomised waitlist-controlled trial in JAMA Psychiatry in 2020, enrolling 24 adults with MDD (not necessarily treatment-resistant). Participants received two psilocybin sessions (20mg/70kg and 30mg/70kg) with full therapeutic support. At four weeks post-treatment, 71% of participants met criteria for remission on the HAMD-17 (Hamilton Depression Rating Scale-17), compared to 10% in the waitlist control. This was accompanied by significant improvements on MADRS (Montgomery–Åsberg Depression Rating Scale) and other secondary measures. The large effect size (Cohen's d > 2.5 for some outcomes) was notable even by psychedelic research standards.

Compass Pathways Phase 2b Trial (COMP360)

Compass Pathways, a UK-based mental health company, completed the largest psilocybin trial to date for TRD: a Phase 2b double-blind randomised controlled trial (NCT03775200) enrolling 233 participants across multiple sites in Europe and North America. Three dose arms were compared: 1mg (control), 10mg, and 25mg psilocybin, each delivered as a single session with therapist support.

Results published in NEJM Evidence in 2022 showed that the 25mg dose produced a statistically significant reduction in depression scores (MADRS) at 3 weeks compared to the 1mg control, with a response rate of 29% (vs 8% for 1mg) and a remission rate of 24% (vs 8%). The 10mg dose did not separate significantly from control. These response rates are lower than earlier open-label trials suggested — reflecting the more rigorous blinded design and the limitation to a single session — but the dose-dependent effect provides important evidence that psilocybin itself, rather than expectancy alone, is driving improvement.

Understanding Depression Outcome Measures

Across psilocybin depression trials, you will encounter three main rating scales:

  • HAMD-17 (Hamilton Depression Rating Scale, 17-item): Clinician-rated scale, scores 0–52. Scores of 0–7 are generally considered normal, 8–13 mild, 14–18 moderate, 19–22 severe, and 23+ very severe. A score reduction of 50%+ from baseline typically constitutes "response"; reaching 0–7 constitutes "remission."
  • QIDS-SR (Quick Inventory of Depressive Symptomatology — Self Report): 16-item self-report, scores 0–27. Scores 0–5 normal, 6–10 mild, 11–15 moderate, 16–20 severe, 21+ very severe.
  • MADRS (Montgomery–Åsberg Depression Rating Scale): 10-item clinician-rated scale, scores 0–60. Scores 0–6 symptom absent/normal, 7–19 mild, 20–34 moderate, 35+ severe.

What the Depression Research Doesn't Yet Show

The psilocybin depression literature, while promising, has important limitations:

  • Long-term outcomes are unclear. Most trials report outcomes at 3–6 months. Data beyond 12 months is limited, and it is unknown what proportion of responders maintain benefit or experience relapse.
  • Large placebo-controlled RCTs for TRD are lacking. The Compass Phase 2b used a low-dose active control (1mg), not an inert placebo — blinding to dose allocation is imperfect. A true placebo-controlled TRD RCT of sufficient size has not yet been completed.
  • Predictor biomarkers are unknown. We cannot yet identify who will respond well versus who will not benefit or may experience adverse reactions.
  • All positive trials have involved extensive therapeutic support. It remains unknown whether psilocybin produces antidepressant effects without concurrent psychotherapy.

Section 3: Psilocybin for Anxiety — The Research

The anxiety evidence base for psilocybin is strongest in a specific population: people with cancer-related existential distress — the profound anxiety and depression that often accompanies a life-threatening diagnosis. Evidence for generalised anxiety as a primary diagnosis is considerably more limited.

Cancer-Related Anxiety: Griffiths et al. 2016

Roland Griffiths and colleagues at Johns Hopkins published a landmark trial in the Journal of Psychopharmacology in 2016, enrolling 51 patients with life-threatening cancer diagnoses and significant depression and anxiety. Using a crossover design comparing high-dose psilocybin (22–30mg/70kg) to a low-dose control, they found that at 6 months post-high-dose session, 78% of participants showed a clinically significant antidepressant response and 83% showed a significant reduction in anxiety — both sustained at 6 months. These effect sizes (Cohen's d around 1.0–1.5) are among the largest reported in psychopharmacology literature. Crucially, 67–75% of participants rated the psilocybin experience as among the most meaningful of their lives.

Cancer-Related Anxiety: Ross et al. 2016

A complementary trial by Stephen Ross and colleagues at New York University, published in the same issue of the Journal of Psychopharmacology, enrolled 29 patients with cancer-related anxiety and depression in a double-blind crossover study comparing psilocybin (0.3mg/kg) to niacin (active placebo). At 6.5 weeks after psilocybin, significant reductions were found in both anxiety (STAI — State Trait Anxiety Inventory) and depression (HAMD) compared to niacin, and 60–80% of participants demonstrated sustained clinically significant improvements at 6.5-month follow-up. The consistency between the Hopkins and NYU findings, across independent research groups and similar design types, strengthens confidence in the effect.

Cancer-Related Anxiety: Grob et al. 2011

An earlier pilot by Charles Grob at the Los Angeles Biomedical Research Institute, published in Archives of General Psychiatry in 2011, enrolled 12 patients with advanced-stage cancer and anxiety in a double-blind crossover trial (psilocybin vs niacin). Despite the small sample, significant reductions in trait anxiety (on the STAI) were found at 1 month and 3 months post-psilocybin, alongside improvements in mood. This trial helped establish the methodological and safety groundwork for the larger 2016 studies.

Generalised Anxiety Disorder

Evidence for psilocybin in generalised anxiety disorder (GAD) as a primary diagnosis — separate from cancer-related anxiety — remains sparse. Some open-label evidence exists suggesting anxiolytic effects, and several ongoing trials are exploring this indication, but no large RCT has specifically targeted GAD. What evidence exists largely derives from secondary outcome measures in depression trials (where anxiety is a common comorbidity) or observational data.

Social Anxiety in Autistic Adults: Danforth et al. 2016

A preliminary open-label study by Alicia Danforth and colleagues, published in Psychopharmacology in 2016, enrolled 12 autistic adults with social anxiety in a dose-escalation design (100–300mg/70kg oral psilocybin). Significant reductions in social anxiety symptoms were found at 6 months post-treatment, with good tolerability and no serious adverse events. This was a small, open-label pilot and should be interpreted cautiously, but it opened a potentially important line of research for a population with very limited current pharmacological options.

Key Distinction: Where the Evidence Is Strong

It is important to be clear that the strongest evidence for psilocybin in anxiety sits squarely in the cancer-related existential anxiety population. This is a specific, relatively narrow clinical context in which existential dread, loss of meaning, and impending mortality interact to produce a form of suffering that may be uniquely responsive to psilocybin's capacity to engender profound, meaning-laden experiences. Extrapolating these findings to generalised anxiety disorder or other anxiety presentations requires caution.

Section 4: Psilocybin for PTSD — The Research

Post-traumatic stress disorder (PTSD) is an area of active research interest for psychedelic-assisted therapy, though the evidence base for psilocybin specifically is considerably less developed than for MDMA — the psychedelic that has received the most attention and the most rigorous clinical testing in PTSD populations.

MDMA Has the Stronger Evidence Base for PTSD

It is critical context that for PTSD specifically, MDMA-assisted therapy (MDMA-AT) currently has a much stronger evidence base than psilocybin. The Mitchell et al. 2023 Phase 3 trial (published in Nature Medicine), enrolling 104 participants with moderate-to-severe PTSD, found that 67% of MDMA-AT participants no longer met diagnostic criteria for PTSD at the primary endpoint (compared to 32% in placebo plus therapy), with a large effect size (Cohen's d = 0.91). MDMA-AT has since received Breakthrough Therapy designation from the FDA, although regulatory approval has faced setbacks. This distinction matters: if you are researching psychedelic-assisted therapy specifically for PTSD, MDMA-AT represents the current leading edge of evidence.

The Rationale for Psilocybin in PTSD

Despite the more limited evidence, psilocybin has a plausible mechanistic rationale for PTSD treatment:

  • Fear extinction: Psilocybin appears to enhance fear extinction learning in preclinical models, potentially allowing traumatic memories to be reprocessed without triggering the same overwhelming fear response.
  • Emotional reprocessing: The psilocybin state may allow individuals to access traumatic material from a position of greater equanimity, reducing avoidance and enabling processing.
  • Meaning-making: Many PTSD sufferers struggle with the existential questions raised by traumatic experience. The mystical or perspective-shift qualities of psilocybin experiences may facilitate meaning-making around trauma.
  • DMN flexibility: PTSD is characterised by hyperactive threat-processing networks and rigid, involuntary trauma re-experiencing. Psilocybin's disruption of entrenched neural patterns may be helpful here as in depression.

Current Psilocybin PTSD Research

Several trials are actively exploring psilocybin for PTSD, including studies at NYU Langone Health and Johns Hopkins, though as of 2026 no completed large RCT of psilocybin specifically for PTSD has been published. Preliminary open-label data and case reports exist, and PTSD is listed as a target indication by multiple research groups. Results from these emerging trials will be important in clarifying where psilocybin sits relative to MDMA in the PTSD treatment landscape.

Why PTSD Presents Specific Risks with Psychedelics

PTSD is not a straightforward indication for psychedelic therapy. Without careful preparation and experienced trauma-informed therapists, psychedelic sessions carry a risk of re-traumatisation — involuntary reliving of traumatic events in an amplified, less controlled way than in conventional trauma therapy. The protocols developed for psilocybin PTSD research draw heavily on trauma-informed care principles, including:

  • Extensive preparation to establish therapeutic alliance and safety
  • Clear agreements on how the participant can signal distress during the session
  • Specific training for therapists in trauma-informed psychedelic facilitation
  • Careful integration support post-session to process what emerged

Anyone considering psilocybin for PTSD outside of a clinical research setting should be aware that the risks are substantially higher than for depression or anxiety, and that the positive outcomes reported in MDMA research occurred in context of exceptionally well-developed therapeutic protocols administered by specifically trained practitioners.

Section 5: Psilocybin for Addiction — The Research

Addiction treatment represents one of the most exciting and best-developed areas of psilocybin research. Two substances — tobacco and alcohol — have been studied with notable results.

Tobacco Cessation: Johnson et al. 2014 and 2017

Matthew Johnson and colleagues at Johns Hopkins conducted a landmark open-label pilot study of psilocybin-assisted therapy for tobacco smoking cessation, published in Psychopharmacology in 2014. Fifteen nicotine-dependent adults who had made multiple prior quit attempts received 2–3 psilocybin sessions (20–30mg/70kg) combined with cognitive behavioural therapy (CBT) for smoking cessation.

The results were remarkable: at the 6-month follow-up, 80% of participants were biologically verified abstinent from smoking — a rate far exceeding standard treatments (nicotine replacement therapy typically achieves approximately 35% at 6 months, and varenicline approximately 40–50%). In a follow-up publication in 2017 reporting longer-term outcomes, 67% remained abstinent at 12 months. A Garcia-Romeu et al. follow-up found that the degree of mystical experience during psilocybin sessions predicted abstinence — the more profound the experience, the better the outcome. These extraordinary figures must be interpreted with caution given the open-label design, the small sample, the self-selected motivated population, and the intensive CBT provided alongside psilocybin. A larger randomised trial comparing psilocybin-assisted therapy to nicotine replacement is underway.

Alcohol Use Disorder: Bogenschutz et al. 2015 and 2022

Michael Bogenschutz and colleagues first published a pilot open-label study of psilocybin for alcohol use disorder in Journal of Psychopharmacology in 2015, enrolling 10 participants with DSM-IV alcohol dependence. Two psilocybin sessions were combined with motivational enhancement therapy. Significant reductions in alcohol craving and drinking days were found both before and particularly after the psilocybin sessions, with the improvement tracking the intensity of the psilocybin experience.

The definitive trial followed: Bogenschutz et al. published a double-blind randomised placebo-controlled trial in JAMA Psychiatry in 2022, enrolling 93 adults with alcohol use disorder. Participants received either two psilocybin sessions (25–40mg/70kg) or diphenhydramine (active placebo), combined with motivational enhancement therapy. The primary outcome was the percentage of heavy drinking days (%HDD) during a 32-week follow-up period. Psilocybin-treated participants showed a significantly greater reduction in %HDD compared to placebo — dropping from 68% at baseline to 24% post-treatment in the psilocybin group, versus 55% in the placebo group. Secondary abstinence outcomes also favoured psilocybin. This represents one of the most rigorous psilocybin trials completed to date and provides strong randomised evidence for alcohol use disorder.

Opioid Use Disorder: Very Early Stage

Psilocybin for opioid use disorder is at a very early stage. The rationale is compelling — opioid addiction is often rooted in trauma, chronic pain, social disconnection, and hopelessness, all of which may be addressed by psilocybin's capacity to produce profound shifts in perspective and meaning. However, the opioid epidemic also involves physical dependence with dangerous withdrawal syndromes, making the clinical picture considerably more complex. As of 2026, research is limited to early feasibility studies and observational data. Psilocybin should not be considered as an alternative to evidence-based opioid use disorder treatments (buprenorphine, methadone, naltrexone) by anyone outside of a clinical trial setting.

General Mechanisms in Addiction

Several mechanisms have been proposed to explain psilocybin's apparent anti-addiction effects:

  • Default mode network rigidity hypothesis: Addiction is characterised by deeply entrenched, habitual thought patterns — craving, seeking, rationalisation — that become automated through chronic use. The DMN is implicated in these self-referential habitual loops. Psilocybin's disruption of DMN activity may temporarily disrupt these automatic patterns, opening a window for new behavioural choices.
  • Increased cognitive flexibility: Beyond the DMN, psilocybin appears to broadly increase cognitive flexibility — the ability to consider problems from new angles and update beliefs in the light of new experience. Addiction involves profound rigidity of thought and behaviour; flexibility may be therapeutic.
  • Lasting value shifts: Many addiction trial participants report that the psilocybin experience led them to fundamentally reprioritise their values — seeing their addiction in the context of what they actually valued in life (relationships, health, purpose) and finding the motivation to change from within. This is qualitatively different from the mechanism of action of anti-craving medications like naltrexone, which work pharmacologically to reduce craving signals.
  • Spiritual/existential dimension: Participants who report a mystical experience during psilocybin sessions — including a sense of connection to something larger than themselves, insights about life meaning, and transcendence of the everyday self — show the best addiction outcomes. This dimension is difficult to quantify but may be central to the mechanism.

How Psilocybin-Assisted Addiction Treatment Differs from Standard Pharmacotherapy

Standard pharmacotherapies for addiction — methadone and buprenorphine for opioids, naltrexone for alcohol and opioids, nicotine replacement therapy — work primarily by modulating neurotransmitter systems to reduce craving or block reward. They typically require daily administration, indefinite use, and do not address the psychological roots of addiction. Psilocybin-assisted therapy operates on a fundamentally different model: a small number of intensive therapeutic sessions aim to produce lasting psychological change — in perspective, values, motivation, and emotional processing — that enables sustained recovery. Whether this approach proves more or less effective than current standards for various populations, and how it might best be combined with existing treatments, are key questions for ongoing research.

Section 6: Psilocybin for OCD — The Research

Obsessive-compulsive disorder (OCD) represents a significant unmet clinical need: approximately 40–60% of patients do not achieve adequate symptom control with first-line treatments (SSRIs and CBT with exposure and response prevention). Psilocybin has attracted interest as a potential treatment partly because of its mechanistic contrast with current approaches.

Moreno et al. 2006: The Foundational Study

The first modern clinical study of psilocybin for OCD was published by Francisco Moreno and colleagues in the Journal of Clinical Psychiatry in 2006. Nine participants with OCD who had not responded to standard treatments received four dose conditions of psilocybin (sub-psychedelic: 25mcg/kg; low: 100mcg/kg; medium: 200mcg/kg; high: 300mcg/kg) in separate sessions. Remarkably, all nine participants showed measurable reductions in OCD symptoms (Yale-Brown Obsessive Compulsive Scale; Y-BOCS) after all dose conditions, with effects appearing within hours and lasting 24 hours or more. No significant adverse events were reported. Some participants reported dramatic symptom relief that lasted beyond the immediate session period. This small, open-label study cannot be considered definitive, but its findings were striking enough to generate significant interest in the indication.

Theoretical Rationale

OCD is characterised by hyperactivation of cortico-striato-thalamo-cortical (CSTC) circuits — neural loops that generate repetitive, intrusive thoughts and compulsive rituals. This rigidity has mechanistic parallels with the DMN overactivation seen in depression and the habitual loops disrupted in addiction. Psilocybin's capacity to broadly disrupt rigid neural patterns — temporarily "loosening" these circuits — provides a plausible rationale for therapeutic effect.

The fact that symptom reduction was observed at even sub-psychedelic doses in Moreno's study is particularly intriguing, suggesting that the mechanism may not require full ego dissolution and may be more directly pharmacological than in depression or addiction.

Current Status and Active Trials

OCD is currently at a very early stage of psilocybin research. No large randomised controlled trials have been completed. Active research groups include Yale University (where Moreno's work has continued) and University College London (UCL). The field awaits larger studies with adequate control arms before conclusions about efficacy can be drawn.

Important caveat: People with OCD should be aware that conventional OCD therapies (particularly Exposure and Response Prevention — ERP — combined with SSRIs) have a well-established evidence base, and any interest in psilocybin for OCD should be pursued through clinical trials rather than self-medication. SSRIs used in OCD treatment may also attenuate psilocybin effects (see Section 9).

Section 7: Psilocybin for Eating Disorders — Emerging Evidence

Eating disorders, particularly anorexia nervosa, represent an area of significant unmet clinical need and have begun to attract research attention from the psychedelic therapy field.

Anorexia Nervosa: The Imperial College London Pilot

Anorexia nervosa has the highest mortality rate of any psychiatric illness — estimated at around 10% over a decade of illness — and remains one of the most treatment-resistant conditions in psychiatry. Conventional treatments produce full recovery in only approximately 50% of patients, and the illness is characterised by profound rigidity of body image, self-perception, and eating cognitions that mirrors the inflexible neural patterns psilocybin appears to disrupt.

The first clinical study of psilocybin for anorexia nervosa was published by Renee Jacques, Natalie Gukasyan, and colleagues (with work from Imperial College London contributing to the conceptual and analytical framework) in Nature Medicine in 2023. This open-label Phase 1 study enrolled 10 adults with anorexia nervosa who received a single high dose of psilocybin (25mg) alongside psychological support. Participants showed improvements in eating disorder psychopathology, body image flexibility, and psychological wellbeing at 1 and 3 months. The study was not designed to assess efficacy — it was primarily a safety and feasibility study — but no serious adverse events were reported and participants tolerated the experience well. The promising early signals have supported the case for larger trials.

Bulimia and Binge Eating Disorder

As of 2026, there is no published clinical data specifically examining psilocybin for bulimia nervosa or binge eating disorder (BED). However, the theoretical rationale is similar to anorexia: both conditions involve rigid, compulsive patterns of behaviour around food, often intertwined with body image disturbance, shame, trauma, and impaired emotional regulation. Psilocybin's effects on cognitive flexibility, emotional processing, and self-perception may be relevant across the eating disorder spectrum.

Strong Caveats for Eating Disorder Populations

Several considerations make eating disorder populations particularly sensitive:

  • Medical fragility: Many individuals with anorexia nervosa have serious physical health complications — cardiac arrhythmias, electrolyte abnormalities, reduced blood pressure — that may interact with psilocybin's cardiovascular effects (transient blood pressure and heart rate increases).
  • Psychiatric complexity: Eating disorders carry high rates of comorbid depression, anxiety, OCD, and personality disorders, complicating the risk profile.
  • Body image vulnerability: Altered bodily perception during psilocybin sessions could theoretically be destabilising for individuals with existing body dysmorphic cognitions, though clinical experience from the initial studies has not confirmed this as a major problem.

This is an area where the research is genuinely at its earliest stage. Do not self-medicate for eating disorders. If you are interested, seek a registered clinical trial.

Section 8: ADHD and Microdosing Psilocybin

ADHD represents a case where popular interest and scientific evidence are particularly misaligned. Anecdotal reports and online communities contain extensive discussion of microdosing psilocybin for ADHD, but formal clinical evidence is essentially absent.

No Clinical Trials Specifically for ADHD

As of 2026, no completed randomised controlled trials specifically examining psilocybin or psilocybin microdosing for ADHD have been published. ADHD is not a primary focus of the major psychedelic research groups, and there are clear mechanistic reasons to be cautious about assuming benefit.

Observational and Survey Evidence

Two frequently cited observational studies provide limited evidence on microdosing:

  • Szigeti et al. 2021 (eLife): The Imperial College London "self-blinding" microdose study enrolled 191 participants who microdosed psychedelics (predominantly psilocybin or LSD) under a partially blinded design (participants prepared their own placebo and drug capsules). Microdosers showed improved mood and focus relative to their own placebo periods, though the effects were small and the study design could not control for expectancy effects. ADHD was not specifically measured.
  • Anderson et al. 2019 (Harm Reduction Journal): A large international survey of self-reported microdosers found that a significant proportion reported microdosing for ADHD, with self-reported improvements in focus and reduced impulsivity. Survey data is subject to profound selection and reporting biases and cannot establish causal relationships.

Why ADHD is Mechanistically Complex for Psilocybin

ADHD is primarily understood as a disorder of the dopaminergic system — specifically, reduced dopaminergic transmission in prefrontal circuits regulating executive function, attention, and impulse control. Established ADHD treatments (methylphenidate, amphetamine derivatives) work by increasing dopamine and noradrenaline availability. Psilocybin, by contrast, works primarily via the serotonergic system — a different neurotransmitter pathway. The theoretical basis for psilocybin specifically targeting the core neurobiological mechanisms of ADHD is therefore much weaker than for depression or anxiety, where serotonergic dysfunction is more centrally implicated.

Potential Drug Interactions with ADHD Medications

People using stimulant medications for ADHD (methylphenidate/Ritalin, amphetamine/Adderall, lisdexamfetamine/Vyvanse) face additional considerations:

  • Stimulants may interact with psilocybin in unpredictable ways, potentially affecting blood pressure and cardiovascular load.
  • Combining psychostimulants with a psychedelic that can itself cause anxiety, agitation, or confusion in some individuals creates a complex risk profile that has not been formally studied.
  • Some individuals report that stimulant medications taken close in time to psilocybin use alter the character of the psilocybin experience significantly.

Given the absence of clinical evidence and the mechanistic uncertainty, no recommendation can currently be made regarding psilocybin for ADHD. Anyone interested should await results of formal clinical trials rather than self-experimenting with a combination that carries unknown risks.

Section 9: Critical Contraindications and Medication Interactions

This section covers some of the most important safety considerations. The following information is not exhaustive. Always consult a healthcare professional regarding your individual circumstances.

Hard Psychiatric Contraindications

Condition Risk Level Reason
Schizophrenia or schizoaffective disorder ABSOLUTE CONTRAINDICATION Psilocybin can trigger, intensify, or permanently worsen psychotic episodes. All clinical trials exclude participants with any personal history of psychosis. Do not use under any circumstances.
Any personal history of a psychotic episode ABSOLUTE CONTRAINDICATION Even a single past psychotic episode, regardless of cause, significantly elevates risk. This includes drug-induced psychosis.
First-degree family history of schizophrenia or psychosis HIGH RISK — Generally excluded Genetic vulnerability to psychosis is a significant risk factor. Most trials exclude participants with first-degree relatives diagnosed with schizophrenia or psychosis.
Bipolar I disorder (with history of mania) Generally contraindicated Psilocybin can trigger manic or hypomanic episodes in individuals with bipolar disorder. Most trials exclude Bipolar I. Some Bipolar II patients have been enrolled in research with extensive additional screening, but this should not be taken as safety clearance outside clinical settings.
Active suicidality Contraindicated outside clinical settings While some trials have included participants with passive suicidal ideation under close clinical supervision, active suicidality without professional support is a clear contraindication. Psilocybin experiences can temporarily intensify difficult emotions, and without support, this can be dangerous.
Significant cardiovascular disease Caution / Consult cardiologist Psilocybin causes transient increases in blood pressure and heart rate during the active period. For individuals with coronary artery disease, arrhythmias, uncontrolled hypertension, or heart failure, these cardiovascular effects could be dangerous.

Medication Interactions

SSRIs and SNRIs (Antidepressants)

Selective serotonin reuptake inhibitors (SSRIs — e.g., fluoxetine, sertraline, citalopram, escitalopram) and serotonin-norepinephrine reuptake inhibitors (SNRIs — e.g., venlafaxine, duloxetine) are among the most commonly prescribed medications in the world and are the mainstay of pharmacological depression and anxiety treatment. Their interaction with psilocybin is important and complex:

  • Chronic SSRI/SNRI use appears to significantly reduce or in some cases eliminate the perceptual and emotional effects of psilocybin, likely through downregulation of 5-HT2A receptors (the primary target of psilocybin). If psilocybin's efficacy depends on strong 5-HT2A activation, chronic SSRI use may blunt therapeutic outcomes.
  • In research settings, participants are sometimes asked to taper and discontinue SSRIs before psilocybin sessions. This must only be done under medical supervision. Abrupt SSRI discontinuation carries serious risks, including severe discontinuation syndrome (dizziness, electric shock sensations, nausea, emotional instability) and risk of depressive relapse.
  • Some SSRIs (particularly fluoxetine, which has a long half-life) may take 4–6 weeks to fully clear from the system, making the timing of any clinical protocol complex.
  • The interaction between SSRIs and psilocybin does not appear to create a direct pharmacological danger (in contrast to MAOIs), but it complicates clinical decision-making enormously.

MAOIs (Monoamine Oxidase Inhibitors)

MAOIs — including phenelzine, tranylcypromine, and moclobemide (a reversible MAOI) — significantly potentiate psilocybin by inhibiting the metabolism of psilocin. This combination can produce dramatically intensified and prolonged effects that are difficult to manage. Some harm reduction contexts specifically flag this combination as dangerous. Anyone taking an MAOI should consider psilocybin absolutely contraindicated without specific medical guidance.

Lithium

The combination of lithium (used in bipolar disorder) and psilocybin has been associated with seizures in case reports. This combination should be considered contraindicated. The mechanism is not fully understood, but may relate to lithium's effects on potassium channels and neuronal excitability. Additionally, as noted above, Bipolar I disorder itself is a contraindication for psilocybin.

Tramadol

Tramadol, an atypical opioid analgesic with serotonergic activity, carries a risk of serotonin syndrome when combined with psilocybin. Serotonin syndrome is a potentially life-threatening condition characterised by agitation, hyperthermia, tachycardia, tremor, and in severe cases, rhabdomyolysis and death. Tramadol should not be taken in close proximity to psilocybin use.

Antipsychotic Medications

Antipsychotic medications (both typical, e.g., haloperidol, and atypical, e.g., olanzapine, risperidone, quetiapine) block dopamine and some serotonin receptors and appear to significantly attenuate or block the effects of psilocybin. Some harm reduction guides note that antipsychotics can be used to abort a difficult psilocybin experience — but this requires immediate medical availability. The fact that antipsychotics block psilocybin's effects does not mean it is safe to combine them or use psilocybin while taking an antipsychotic; the underlying condition for which antipsychotics are prescribed (psychosis, bipolar disorder, schizophrenia) is itself typically a contraindication.

Other Serotonergic Substances

Any substance that increases serotonergic activity — including other psychedelics, St John's Wort (hypericum), certain migraine medications (triptans), and some pain medications — may interact with psilocybin in unpredictable ways and should be avoided without medical guidance.

Section 10: What the Research Does and Doesn't Show

Given the scale of media coverage about psychedelic medicine, it is worth being precise about what the scientific evidence currently supports and where significant gaps remain.

What the Research DOES Show

  • Significant short-term antidepressant and anxiolytic effects in clinical settings. Across multiple trials, psilocybin produces large reductions in depression and anxiety scores compared to baseline and, in some cases, compared to control conditions. Effect sizes are frequently larger than those typically found in antidepressant drug trials.
  • Good safety profile in screened populations. In trials with appropriate participant screening (excluding psychosis history, bipolar I, cardiovascular disease, high-risk medication use), serious adverse events have been rare. Psilocybin does not appear to produce physiological dependence and has low potential for harmful use in clinical populations.
  • Effects persist weeks to months after treatment. Unlike most pharmacological treatments that require daily dosing, psilocybin-associated improvements in depression and anxiety have persisted for 3–6 months in many trial participants after just one or two sessions.
  • Dose-dependent effects demonstrated in at least one large RCT (Compass Pathways). The Phase 2b trial provides evidence that the 25mg dose specifically produces effects beyond expectancy, supporting the pharmacological contribution of psilocybin itself.
  • Strong evidence for cancer-related existential distress. Two independent, reasonably well-designed RCTs found large and durable reductions in anxiety and depression in cancer patients, representing the most replicated finding in the field.

What the Research DOESN'T Show Yet

  • Long-term (12+ month) efficacy from large RCTs. Whether treatment gains are maintained beyond 6 months, or what proportion of participants relapse, is not yet established by large-scale controlled data.
  • Safety outside clinical settings. All clinical evidence is from environments with extensive screening, therapeutic support, and immediate professional access. Outcomes in uncontrolled settings may differ substantially.
  • Comparative effectiveness vs established treatments in general populations. The NEJM psilocybin vs escitalopram comparison was underpowered for definitive conclusions, and most trials have not directly compared psilocybin-assisted therapy to gold-standard psychotherapy (such as CBT).
  • Predictive biomarkers or patient selection criteria. We cannot yet identify from biological, psychological, or demographic variables who will respond best, who is at elevated risk of adverse reactions, or what dose schedule is optimal for different conditions.
  • Efficacy of psilocybin without psychotherapeutic support. Clinical trials virtually always combine psilocybin with extensive therapeutic preparation and integration. Whether the drug alone produces comparable outcomes is unknown and untested.

Common Misconceptions

  • Misconception: Clinical research is studying psilocybin as a recreational substance. Clinical research is studying psilocybin as a therapeutic tool within a highly structured clinical framework, not as a drug used for pleasure or recreation. The two contexts are fundamentally different.
  • Misconception: Positive trial results mean psilocybin is safe for general use. Trial results apply to screened populations receiving treatment in controlled conditions. These results do not validate unsupervised use.
  • Misconception: If psilocybin works for depression in trials, it will work for my depression. Individual variation in response is large, contraindications are significant, and outside clinical settings the safety net of screening and professional support is absent.

Section 11: Accessing Clinical Trials

If you are interested in psilocybin-assisted therapy and are not in a jurisdiction where it is legally available therapeutically, participation in a clinical research trial is the primary legitimate pathway. Here is how to navigate the process.

Finding Trials: ClinicalTrials.gov

ClinicalTrials.gov is the primary US registry (maintained by the National Institutes of Health) for clinical research studies. It lists thousands of trials conducted worldwide — not just in the United States. To search for psilocybin trials:

  1. Go to clinicaltrials.gov
  2. Search for "psilocybin" in the search box
  3. Filter by Status: "Recruiting" to find trials currently accepting participants
  4. Filter by Condition to narrow to your relevant diagnosis (e.g., "depression," "PTSD," "OCD")
  5. Filter by Country if you need a local trial

Understanding a Trial Listing

Each trial listing includes several key pieces of information:

  • NCT Number: The unique identifier (e.g., NCT03775200). Use this to track a specific trial.
  • Phase: Phase 1 (safety), Phase 2 (efficacy and dosing), Phase 3 (confirmatory efficacy, large scale). Phase 2 and 3 trials are most relevant for potential participants seeking treatment.
  • Eligibility criteria: Inclusion and exclusion criteria define who can and cannot enrol. Read these carefully — they will specify diagnostic requirements, medication conditions, age ranges, and contraindications.
  • Locations: Sites where the trial is conducted.
  • Contact information: Usually a principal investigator or study coordinator email or phone number for enquiries.

What to Expect from Screening

Being enrolled in a psilocybin trial typically involves a thorough screening process:

  • Diagnostic interview to confirm the condition being studied
  • Medical history and physical examination, including cardiovascular screening
  • Psychiatric history including any personal or family history of psychosis
  • Review of all current medications
  • Psychological assessment
  • Urine drug screen

This screening process is thorough precisely because the research community takes participant safety seriously. Exclusion at screening is common and does not reflect on the potential participant personally — it reflects the appropriateness of the trial for their particular situation.

Paid vs Volunteer Participation

Compensation varies widely. Some trials offer modest financial compensation for time and travel. Others are purely volunteer. Many trials in academic settings offer the treatment (including preparatory and integration therapy) free of charge to accepted participants, which can represent substantial financial value given the cost of these services in private settings.

Trial Trackers and Patient Advocacy Resources

  • Psychedelic Alpha Trial Tracker (psychedelicalpha.com/data/trials) — independent aggregator of psychedelic research trials with status updates
  • MAPS Patient Advocacy (maps.org) — Multidisciplinary Association for Psychedelic Studies; information on trials and patient advocacy
  • UK: NIHR Clinical Trials (nihr.ac.uk/clinical-trials/) — National Institute for Health and Care Research trial listings
  • Australia: ANZCTR (anzctr.org.au) — Australia and New Zealand Clinical Trials Registry, including TGA-approved trials

Section 12: Integration Therapy for Mental Health

Integration therapy — the psychological work done after a psilocybin session to process, contextualise, and apply the insights and experiences that arose — is considered a critical component of psilocybin-assisted therapy by virtually all clinical researchers in the field. Understanding what integration is and why it matters is essential context for anyone considering psilocybin for mental health purposes.

What is Integration Therapy?

A psilocybin experience typically generates a great deal of psychological material: memories, emotions, insights, imagery, and shifts in perspective. Integration therapy provides structured support to help the individual make sense of this material and translate it into meaningful, lasting changes in thought, behaviour, and wellbeing. Without integration, the insights of the session may feel vivid and important during and immediately after, but gradually fade without being embedded in the participant's life.

Integration is not crisis management or processing of bad experiences only — it is equally important after positive or profoundly meaningful experiences, which also require careful contextualisation to yield lasting benefit.

Why Integration Matters

The research literature consistently suggests that psilocybin experiences alone, without therapeutic context, produce more modest and less durable effects than those embedded in a full therapeutic structure including integration. Some researchers argue that the psilocybin session itself is best understood as a catalyst or window of neuroplasticity, during which the therapeutic work done in integration has enhanced impact. Integration is, on this view, where the lasting change actually happens.

Integration Modalities

Integration can draw on a range of therapeutic approaches, and competent integration therapists typically adapt their approach to the needs of the individual and the nature of what arose in the session:

  • CBT-informed integration: Examining distorted beliefs and automatic thought patterns surfaced during the session; behavioural planning based on insights
  • Acceptance and Commitment Therapy (ACT): Working with values clarification and psychological flexibility, which aligns well with the ACT-relevant mechanisms of psilocybin described in Section 1
  • Somatic therapy: Processing bodily sensations and trauma held in the body, which may emerge during psilocybin sessions
  • Mindfulness-based approaches: Deepening the capacity for present-moment awareness and non-judgmental observation of experience that psilocybin may have temporarily revealed
  • Narrative therapy: Helping the individual construct a new, more empowering narrative about their life and identity based on what arose in the session

Timeline and Structure

In clinical trials, integration typically involves 2–4 sessions before the psilocybin day (preparation) and 2–8 sessions afterwards (integration), spread over 4–8 weeks. Longer-term follow-up contacts are sometimes included. In the most intensive protocols (such as those developed by MAPS for MDMA-AT, which have influenced psilocybin protocols), each therapeutic dyad (two therapists per participant) receives specific training in the integration approach used.

Online Integration Resources

A growing number of integration therapists offer online sessions, which has expanded access for people in areas without local options. However, the quality of online integration services varies considerably. Directories such as Psychedelic Support (psychedelic.support) allow filtering for online practitioners.

Section 13: Finding a Psychedelic-Informed Therapist

Whether in a legal therapeutic context (Australia, Oregon, Colorado) or seeking integration support outside of a clinical trial, finding a qualified and ethical psychedelic-informed therapist is critically important. The field is growing rapidly, but so are the opportunities for exploitation and poorly qualified practice.

Therapist Directories

  • MAPS Therapist Directory (maps.org) — trained MDMA-AT therapists; many are also knowledgeable about psilocybin
  • Psychedelic Support (psychedelic.support) — searchable directory of integration therapists and psychedelic-informed practitioners worldwide
  • Zendo Project (zendoproject.org) — harm reduction-focused; not a therapy directory per se, but provides trained support at events and crisis contexts
  • GRIP (Global Registry of Psychedelic Practitioners) — emerging credentialing body for psychedelic practitioners; directory in development
  • Psychedelic Alpha (psychedelicalpha.com) — independent information source listing integration resources and practitioners

Questions to Ask a Prospective Therapist

  • What is your training background in psychedelic-assisted therapy specifically? (e.g., MAPS training, Synthesis Institute, CIIS Certificate Programme)
  • Are you licensed as a mental health professional (therapist, psychologist, psychiatrist) in this jurisdiction?
  • Do you receive ongoing supervision specifically for psychedelic work?
  • What are your emergency protocols if I experience a difficult reaction?
  • How many clients have you supported through psilocybin or other psychedelic experiences?
  • What is your integration approach and which modalities do you work with?

Red Flags to Watch For

The psychedelic therapy space has been associated with a number of ethical violations. The following should raise serious concerns:

  • Offering to provide or source psilocybin: In jurisdictions where psilocybin is not legally available therapeutically, a therapist offering to provide or source the substance is operating illegally and unethically. This is a significant red flag.
  • Sexual dual relationships: Sexual boundary violations in psychedelic therapy contexts have been documented in the literature and represent a serious exploitation of the vulnerability that arises during these experiences. Any sexual suggestion or contact by a therapist is grounds for immediate withdrawal and complaint.
  • No integration support: A practitioner who offers only the session experience without preparation and integration is not providing what the evidence supports as best practice.
  • Pressure to continue treatment beyond your comfort: Legitimate therapists work at your pace and respect your autonomy.
  • No emergency protocol: A therapist who cannot explain what they would do in a medical or psychiatric emergency during a session is not adequately prepared.

Cost and Accessibility

Psychedelic-assisted therapy in legal contexts and integration therapy with qualified practitioners can be expensive, particularly in private settings. Consider:

  • Many integration therapists offer sliding scale fees for clients with financial constraints — ask directly.
  • Clinical trials often provide the entire therapeutic programme free of charge to enrolled participants.
  • Some therapists offer group integration sessions at lower per-person cost than individual sessions.
  • Community integration circles (peer-led) are not a substitute for professional therapy but can provide valuable supplementary support at low or no cost.

Section 14: Frequently Asked Questions — Psilocybin and Mental Health

Is psilocybin approved as a psychiatric treatment anywhere?

Yes, in a small number of jurisdictions. Australia became the first country to formally approve psilocybin (alongside MDMA) as a prescription medicine for specific conditions in February 2023, with availability through authorised psychiatrists from July 2023 — psilocybin for treatment-resistant depression, and MDMA for PTSD. Oregon (USA) launched a regulated psilocybin services framework in 2023, allowing licensed facilitators to administer psilocybin in authorised service centres. Colorado followed with a similar model in 2024. However, psilocybin remains a Schedule I controlled substance at the US federal level, and in most of the world — including the UK, EU member states, and Canada — it is not approved as a prescription medication and is only accessible through licensed clinical research trials.

How long do the mental health benefits of psilocybin last?

This varies considerably between individuals and conditions, and the evidence base for long-term durability is still developing. In depression trials, meaningful improvements have been documented at 3–6 month follow-ups across multiple studies, with some participants reporting sustained remission. In the cancer anxiety trials, effects persisted at 6–6.5 month follow-ups. In tobacco cessation research, 67% of participants remained abstinent at 12 months. However, relapse is also documented — this is not a one-time cure. In clinical protocols, therapists often work with participants to develop ongoing mental health practices (mindfulness, continued psychotherapy, lifestyle changes) that may help sustain benefits. Long-term (1–2 year) follow-up data from large randomised trials is currently limited.

Can I take psilocybin if I'm currently on antidepressants?

This requires careful consideration and medical guidance. SSRIs and SNRIs — the most commonly prescribed antidepressants — may significantly reduce psilocybin's effects, potentially making therapeutic sessions less effective. In research protocols, participants are sometimes asked to taper and discontinue SSRIs prior to psilocybin sessions under close medical supervision. However, abruptly stopping an antidepressant carries its own significant risks, including discontinuation syndrome and depressive relapse. MAOIs create a more dangerous interaction and should be considered a contraindication (see Section 9). If you are taking any psychiatric medication and are considering psilocybin, this conversation must happen with a qualified healthcare professional — it is not a decision to make independently.

What is the difference between psilocybin-assisted therapy and self-medicating at home?

The differences are substantial and clinically significant. Clinical psilocybin-assisted therapy involves: thorough medical and psychiatric screening to identify contraindications; multiple preparatory therapy sessions; administration in a carefully designed therapeutic environment with two trained therapists present throughout; immediate access to medical support if needed; and multiple integration therapy sessions afterwards. Self-medicating at home involves none of these elements. The outcomes reported in clinical trials reflect the combined effect of psilocybin plus this entire therapeutic structure. Without these safeguards, the risk of adverse events — including challenging psychological experiences, cardiovascular events, triggering latent psychiatric conditions, or simply wasted opportunity — is substantially higher, and the likelihood of achieving therapeutic outcomes is likely lower. Self-medication should be approached with full awareness of this difference.

What does a challenging or difficult psilocybin experience mean for mental health?

A "difficult" or "challenging" psilocybin experience — characterised by fear, anxiety, confusion, paranoia, or confronting difficult content — does not necessarily indicate a bad outcome. In clinical settings, therapists are trained to work with difficult material rather than suppress it, recognising that difficult experiences can yield important therapeutic insights when properly supported. Some research suggests that participants who work through challenging content during a session show good outcomes. However, this support structure — two trained therapists, a safe physical environment, immediate capability to intervene if needed — is essential context. A difficult experience without support can lead to lasting distress, including in rare cases persisting anxiety, flashbacks, or worsened symptoms. The term "bad trip" reflects the cultural context of recreational use; clinical trials use the term "challenging experience" and manage it very differently.

Is psilocybin addictive? Can it create dependence?

Psilocybin does not appear to produce physical dependence or a clinically significant withdrawal syndrome. Tolerance to psilocybin's effects develops rapidly with repeated use (within a few days of consecutive use), which naturally limits escalation of use. In population studies, psilocybin consistently ranks among the substances least associated with harmful use, dependence, and emergency hospital presentations. Importantly, psilocybin does not significantly activate the mesolimbic dopamine reward pathway in the same way as addictive substances (opioids, stimulants, alcohol). The risk of developing compulsive use behaviour appears low. This is one reason why psilocybin is actively studied as an addiction treatment. However, psychological dependence — relying on psilocybin experiences rather than developing independent coping skills — is a theoretical concern that good integration therapy is designed to address.

What is Hallucinogen Persisting Perception Disorder (HPPD) and how common is it?

Hallucinogen Persisting Perception Disorder (HPPD) is a rare condition in which certain perceptual disturbances experienced during a psychedelic experience — such as visual trails, halos around objects, geometric patterns, afterimages, or changes in colour perception — persist or re-appear after the substance has left the body. HPPD is classified into two types: HPPD I (occasional, non-distressing flashbacks to perceptual effects) and HPPD II (more persistent, clinically significant perceptual changes that cause distress or functional impairment). Estimates of prevalence vary widely and are complicated by underreporting and inconsistent diagnostic criteria, but HPPD II appears rare in screened clinical populations — it has been rarely if ever reported in published psilocybin clinical trials with screened participants. Risk factors may include prior heavy psychedelic use, cannabis use alongside psychedelics, and use in individuals with pre-existing anxiety or personality vulnerabilities. If persistent visual disturbances occur after psilocybin use, consultation with a psychiatrist familiar with psychedelic medicine is advisable.

How does psilocybin compare to ketamine for depression?

Ketamine (and its S-enantiomer esketamine, marketed as Spravato) is currently the only rapidly-acting antidepressant approved by the FDA for treatment-resistant depression and major depression with acute suicidal ideation. Ketamine works primarily via NMDA glutamate receptor antagonism — a completely different mechanism from psilocybin's serotonergic action. Both produce rapid antidepressant effects (within hours to days rather than weeks), distinguishing them from conventional SSRIs. However, ketamine's effects are generally short-lived without repeated infusions (typically administered twice weekly for 3 weeks), while psilocybin appears to produce more durable effects from fewer sessions. Ketamine carries a dissociative rather than truly psychedelic quality, is less likely to produce a full mystical experience, and has recognised potential for misuse and dependence in recreational contexts (though clinical use is monitored). The two approaches are not directly compared in head-to-head trials; both represent important advances in the rapidly-acting antidepressant landscape for different patient populations.

What happens if I have a difficult experience during a psilocybin session? Who can I call?

In a clinical trial or legal therapeutic session, two trained therapists are present throughout the experience and are trained to manage difficult reactions using grounding techniques, compassionate presence, and if necessary, the administration of a benzodiazepine or antipsychotic to moderate or terminate the experience. Outside of clinical contexts, resources include: Fireside Project (US, 62-FIRESIDE / 623-473-7433) — a peer support hotline specifically for difficult psychedelic experiences; Zendo Project — harm reduction support; MAPS Zendo Psychedelic Harm Reduction training network. If someone is in immediate physical danger, contact emergency services. It is also worth noting that having trusted, calm, sober individuals (often called a "sitter" or "trip sitter") present during any non-clinical psychedelic experience is a basic harm reduction practice that significantly reduces the risk of a difficult experience escalating into a crisis.

What is the legal status of psilocybin therapy in the UK?

In the United Kingdom, psilocybin is classified as a Schedule 1 controlled substance under the Misuse of Drugs Act 1971 — meaning it is considered to have no recognised medicinal value and very high potential for abuse, in the eyes of current law. Possession, supply, and production are criminal offences. Psilocybin-assisted therapy is not available as an approved treatment in the UK. Access is possible only through licensed clinical research trials approved by the Medicines and Healthcare products Regulatory Agency (MHRA) and an ethics committee. The UK has seen significant academic research activity (Imperial College London, King's College London) but regulatory change has lagged behind Australia and some US states. The charity Drug Science and various advocacy groups have been campaigning for rescheduling to enable clinical access, and there have been parliamentary discussions, but as of 2026 no change has been enacted. Anyone in the UK interested in accessing psilocybin therapy should search the NIHR Clinical Trials website (nihr.ac.uk) for actively recruiting UK-based trials.

Explore Condition-Specific Pages

Depression

Detailed research on psilocybin for treatment-resistant depression and major depressive disorder, including clinical trial results and mechanisms of action.

Learn More

Anxiety

Studies on psilocybin for existential anxiety, end-of-life anxiety, cancer-related distress, and general anxiety disorders.

Learn More

PTSD

Emerging research on psychedelics for post-traumatic stress disorder, trauma processing, and the comparison with MDMA-assisted therapy.

Learn More

Addiction

Research on psilocybin for substance use disorders including alcohol and tobacco, with full trial summaries and mechanism explanations.

Learn More

OCD

Research on psilocybin for obsessive-compulsive disorder, including the foundational Moreno et al. 2006 study and current trials.

Learn More

Eating Disorders

Emerging early-stage research on psilocybin for anorexia nervosa and related conditions, with important safety caveats.

Learn More

ADHD

Considerations for individuals with ADHD, including anecdotal and observational reports on microdosing and key caveats.

Learn More

Bipolar Disorder

Critical safety considerations, contraindications, and the nuanced picture for bipolar I vs bipolar II in psychedelic research.

Learn More

Related Resources

Psychedelic Therapy

Therapeutic frameworks and clinical approaches.

 Integration

Processing insights for lasting wellbeing.

 Safety & Harm Reduction

Contraindications and safe-use guidance.

 Microdosing

Sub-perceptual dosing — evidence and considerations.

 Communities

Peer support and shared experiences.

 General FAQ

Frequently asked questions about psilocybin.